U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT06892288) titled 'A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants with PMM2-CDG' on Feb. 06.
Brief Summary: This study is evaluating the safety, effectiveness, and how the body absorbs, distributes, and eliminates GLM101, for participants with PMM2-CDG, including children, adolescents, and adults. Researchers will compare participants receiving GLM101 to those receiving a placebo to see if GLM101 improves symptoms of PMM2-CDG.
The study includes two treatment parts: a 24-week double blind placebo-controlled treatment period (Part A), and a 24-week open-label phase where every participant will receive GLM101(Part ...